Last reviewed · How we verify
Condylox (podophyllotoxin)
Condylox (generic name: podophyllotoxin) is a podophyllotoxin drug developed by Actavis Labs Ut Inc. It is currently FDA-approved (first approved 1990) for Topical treatment of anogenital warts.
Condylox works by disrupting cell division and preventing the growth of abnormal cells.
Condylox, also known as Podofilox, is a small molecule cream used to treat genital warts and molluscum contagiosum. It is applied topically, either by a healthcare provider or the patient themselves, and is not recommended for HPV infections without external warts.
At a glance
| Generic name | podophyllotoxin |
|---|---|
| Sponsor | Actavis Labs Ut Inc |
| Drug class | podophyllotoxin |
| Target | Glucocorticoid receptor |
| Therapeutic area | Other |
| Phase | FDA-approved |
| First approval | 1990 |
Mechanism of action
Mechanism of Action. Treatment of genital warts with podofilox results in necrosis of visible wart tissue. The exact mechanism of action is unknown.
Approved indications
- Topical treatment of anogenital warts
Common side effects
- Burning
- Pain
- Inflammation
- Erosion
- Itching
- Tingling
Key clinical trials
- A Study Comparing BL-B01D1 Combined With Tislelizumab Versus Platinum-containing Chemotherapy Combined With Tislelizumab as First-line Treatment in Patients With Extensive-stage Small Cell Lung Cance (PHASE3)
- Ibrutinib Before and After Stem Cell Transplant in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (PHASE3)
- A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC) (PHASE3)
- A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003) (PHASE1,PHASE2)
- A UGT1A1 Genotype-Directed Study of Belinostat Pharmacokinetics and Toxicity (PHASE2)
- Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas (PHASE2,PHASE3)
- Using Biomarker Tests to Select and Test New, Personalized Treatments for Extensive Stage Small Cell Lung Cancer, PRISM Study (PHASE2)
- Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Condylox CI brief — competitive landscape report
- Condylox updates RSS · CI watch RSS
- Actavis Labs Ut Inc portfolio CI
Frequently asked questions about Condylox
What is Condylox?
How does Condylox work?
What is Condylox used for?
Who makes Condylox?
What is the generic name of Condylox?
What drug class is Condylox in?
When was Condylox approved?
What development phase is Condylox in?
What are the side effects of Condylox?
What does Condylox target?
Related
- Drug class: All podophyllotoxin drugs
- Target: All drugs targeting Glucocorticoid receptor
- Manufacturer: Actavis Labs Ut Inc — full pipeline
- Therapeutic area: All drugs in Other
- Indication: Drugs for Topical treatment of anogenital warts
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing